An asthma drug biotech that was acquired in a deal with GSK plc worth up to $1.4 billion is now at the center of a lawsuit, ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Genentech announced a third round of layoffs, affecting 143 jobs, as part of its strategic workforce adjustments, amid broader job cuts across various sectors in Northern California.

Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...

The study, led from the University of Utah, analyzed 3,286 hospitals across the country, using data from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, which ran ...

Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech ...